For HER2-positive gastric cancer, the landmark ToGA trial showed that combining Trastuzumab with chemotherapy significantly improved survival rates, setting a precedent for targeted therapy in gastric cancer [3]. This evidence concerns the gene ERBB2 and gastric cancer.